Features of the use of oral anticoagulants in clinical practice: focus on gastrointestinal complications

Abstract

The review article presents dates about the physiology and pathophysiology of the hemostasis system, discusses the features of the use of oral anticoagulants in clinical practice. Oral anticoagulants are drugs characterized by predictable pharmacokinetics and pharmacodynamics, a favorable efficacy and safety profile. The article considers the main clinical and pharmacological characteristics of apixaban, rivaroxaban and dabigatran (bioavailability, metabolism, excretion); factors that increase the risk of gastrointestinal bleeding associated with anticoagulant therapy; drug interactions; the possibility of gastroprotection in patients taking oral anticoagulants. In real clinical practice, the reason for not prescribing or unreasonably reducing the dose of oral anticoagulants is the fear of bleeding. In this case, the risks of bleeding, as a rule, are overestimated. Knowledge of bleeding risk factors, prognostic scales and management of risk factors is an approach that can improve the safety of anticoagulant therapy. In clinical practice, the choice of the ideal oral anticoagulants, in addition to taking into account the risk of bleeding, should be based on a comprehensive assessment, including an assessment of the patient's age, risk of stroke and coronary events, renal function, and predicted compliance.

Keywords

apixaban / rivaroxaban / dabigatran / pharmacokinetics / bioavailability / adverse drug reactions / gastrointestinal bleeding

References

[1] Pathophysiology: textbook: Ed. by V.V. Novitsky, E.D. Goldberg, O.I. Urazova. Moscow: GEOTAR-Media, 2009. Vol. 2. 640 p. (In Russ.)

[2] Патофизиология: учебник: в 2 т. / под ред. В.В. Новицкого, Е.Д. Гольдберга, О.И. Уразовой. Москва: ГЭОТАР-Медиа, 2009. Т. 2. 640 с.

[3] Forge BI. Cellular and molecular mechanisms of regulation of the hemostasis system in normal and pathology. Chita: Express Publishing, 2010. (In Russ.)

[4] Кузник Б.И. Клеточные и молекулярные механизмы регуляции системы гемостаза в норме и патологии. Чита: Экспресс-издательство, 2010.

[5] Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009;373(9658): 155–166. DOI: 10.1016/S0140-6736(09)60040-4

[6] Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited // Lancet. 2009. Vol. 373, No. 9658. P. 155–166. DOI: 10.1016/S0140-6736(09)60040-4.

[7] Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis — current understanding from an epidemiological point of view. Br J Haematol. 2010;149(6):824–833. DOI: 10.1111/j.1365-2141.2010.08206.x

[8] Lijfering W.M., Rosendaal F.R., Cannegieter S.C. Risk factors for venous thrombosis — current understanding from an epidemiological point of view // Br J Haematol. 2010. No. 6. Р. 824–833. DOI: 10.1111/j.1365-2141.2010.08206.x

[9] Sloan E, Wright T, Zuo Y. Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers. Lupus. 2021;30(5):828–832. DOI: org/10.1177/09612033211002256

[10] Sloan E., Wright T., Zuo Y. Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers // Lupus. 2021. Vol. 30, No. 5. P. 828–832. DOI: 10.1177/09612033211002256

[11] Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 2013;122(20):3415–3422. DOI: org/10.1182/blood-2013-05-427708

[12] Samad F., Ruf W. Inflammation, obesity, and thrombosis // Blood. 2013. Vol. 122, No. 20. P. 3415–3422. DOI: 10.1182/blood-2013-05-427708

[13] Previtali E, Bucciarelli P, Passamonti SM, et al. Risk factors for venous and arterial thrombosis. Blood Transfus. 2011;9(2):120–138

[14] Previtali E., Bucciarelli P., Passamonti S.M., et al. Risk factors for venous and arterial thrombosis // Blood Transfus. 2011. Vol. 9, No. 2. P. 120–138.

[15] Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics — 2010 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2019;121;e46–e215. DOI: 10.1161/CIRCULATI0NAHA.109.192667

[16] Lloyd-Jones D., Adams R.J., Brown T.M. et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation. 2019. Vol. 121. P. e46–e215. DOI: 10.1161/CIRCULATIONAHA.109.192667

[17] Bergmark BA, Bhatt DL, Braunwald E, et al. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. Diabetes Care. 2018;41(3):577–585. DOI: org/10.2337/dc17-1736

[18] Bergmark B.A., Bhatt D.L., Braunwald E., et al. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease // Diabetes Care. 2018. Vol. 41, No. 3. P. 577–585. DOI: 10.2337/dc17-1736

[19] Cetinkal G, Kocas BB, Ser OS, et al. Assessment of the Modified CHA2DS2VASc Risk Score in Predicting Mortality in Patients Hospitalized With COVID-19. Am J Cardiol. 2020;135:143–149. DOI: org/10.1016/j.amjcard.2020.08.040

[20] Cetinkal G., Kocas B.B., Ser O.S., et al. Assessment of the Modified CHA2DS2VASc Risk Score in Predicting Mortality in Patients Hospitalized With COVID-19 // Am J Cardiol. 2020. Vol. 135. P. 143–149. DOI: org/10.1016/j.amjcard.2020.08.040

[21] Tamizifar B, Fereyduni F, Esfahani MA, et al. Comparing three clinical prediction rules for primarily predicting the 30-day mortality of patients with pulmonary embolism: The "Simplified Revised Geneva Score," the "Original PESI," and the "Simplified PESI". Adv Biomed Res. 2016;5:137. DOI: org/10.4103/2277-9175.187372

[22] Tamizifar B., Fereyduni F., Esfahani M.A., et al. Comparing three clinical prediction rules for primarily predicting the 30-day mortality of patients with pulmonary embolism: The "Simplified Revised Geneva Score," the "Original PESI," and the "Simplified PESI" // Adv Biomed Res. 2016. Vol. 5. P. 137. DOI: org/10.4103/2277-9175.187372

[23] Clinical Pharmacology: Study / Ed. by V.G. Kukesa. Moscow: GEOTAR-Media, 2006. 944 p. (In Russ.)

[24] Клиническая фармакология: учеб. / под ред. В.Г. Кукеса. М.: ГЭОТАР-Медиа, 2006. 944 с.

[25] Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–1507. DOI: org/10.1093/europace/euv309

[26] Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015. Vol. 17. P. 1467–1507. DOI: 10.1093/europace/euv309

[27] Erosive-ulcerative lesions of the gastroduodenal zone in stressful situations (operations, injury and shock) and severe diseases of internal organs. KRSU Bulletin. 2014;14(1):179–182. (In Russ.)

[28] Батырова А.Н., Бердалина Г.С., Тажиева А.Е. и др. Эрозивно-язвенные поражения гастродуоденальной зоны при стрессовых ситуациях (операциях, травме и шоке) и тяжелых заболеваниях внутренних органов // Вестник КРСУ. 2014. Т. 14, № 1. С. 179–182.

[29] Tavlueva EV, Savkova ON, Zernova EV et al. Frequency of use of oral anticoagulants in real-life clinical practice in patients hospitalized with acute ischemic stroke. Russian Journal of Cardiology. 2022;12(27):74–79. (In Russ.)

[30] Тавлуева Е.В., Савкова О.Н., Зернова Е.В. и др. Частота использования пероральных антикоагулянтов в реальной клинической практике у пациентов, госпитализированных с острым ишемическим инсультом // Российский кардиологический журнал. 2022. Т 12, № 27. С. 74–79.

[31] Moiseev S. Direct oral anticoagulants for prevention of recurrent stroke in patients with atrial fibrillation. Clin Pharmacolоgiya i terapiya. 2021;30(3):57–66. (In Russ.) DOI: 10.32756/0869-5490-2021- 3-57-66

[32] Моисеев С.В. Прямые оральные антикоагулянты в профилактике повторного инсульта у пациентов с фибрилляцией предсердий // Клиническая фармакология и терапия. 2021. Т. 3, № 30. С. 57–66. DOI: 10.32756/0869-5490-2021- 3-57-66.

[33] Raval AN, Cigarroa JE, Chung MK, et al. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation. 2017;135(10):e647. DOI: 10.1161/CIR.0000000000000477

[34] Raval A.N., Cigarroa J.E., Chung M.K., et al. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association // Circulation. 2017. Vol. 135, No. 10. Р. e647. DOI: 10.1161/CIR.0000000000000477

[35] Сlinical guidelines: Atrial fibrillation and flutter. Ministry of Health of the Russian Federation. Moscow, 2020. 185 p. (In Russ.)

[36] Клинические рекомендации: Фибрилляция и трепетание предсердий. Москва, 2020. 185 с. https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP-unlocked.pdf

[37] Official Instruction for the drug Xarelto®. https://www.rlsnet.ru/tn_index_id_43277.htm [Available from: 23.07.2021]. (In Russ,)

[38] Официальная инструкция к препарату Ксарелто®. https://www.rlsnet.ru/tn_index_id_43277.htm [дата обращения: 23.07.2021]

[39] Official Instructions for the drug Pradaxa®. https://www.rlsnet.ru/tn_index_id_42850.htm [Available from: 23.07.2021]. (In Russ.)

[40] Официальная инструкция к препарату Прадакса®. https://www.rlsnet.ru/tn_index_id_42850.htm [дата обращения: 23.07.2021].

[41] Official Instruction for the drug Eliquis®. https://www.vidal.ru/drugs/eliquis__38823 [Available from: 23.07.2021]. (In Russ.)

[42] Официальная инструкция к препарату Эликвис®. https://www.vidal.ru/drugs/eliquis__38823 [дата обращения: 23.07.2021]

[43] Camm AJ, Amarenco P, Haas S, et al. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag. 2014;10:425–434. DOI: 10.2147/VHRM.S63298

[44] Camm A.J., Amarenco P., Haas S., et. al. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation // Vasc Health Risk Manag. 2014. Vol. 10: P.425–434. DOI: 10.2147/VHRM.S63298

[45] Lip G, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions. European Journal of Cardiology. 2014;35(45): 3155–3179. DOI: 10.1093/eurheartj/ehu298

[46] Lip G., Windecker S., Huber K., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions // Eur J of Cardiol. 2014. Vol. 35, No. 45. Р. 3155–3179. DOI: 10.1093/eurheartj/ehu298

[47] Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5): 373–498. DOI: 10.1093/eurheartj/ehaa612.

[48] Hindricks G., Potpara T., Dagres N., et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC // Eur Heart J. 2021. Vol. 42, No. 5. P. 373–498. DOI: 10.1093/eurheartj/ehaa612

[49] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. DOI: 10.1056/NEJMoa0905561

[50] Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation // N Engl J Med. 2009. Vol. 361, No. 12. P. 1139–1151. DOI: 10.1056/NEJMoa0905561

[51] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. DOI: 10.1056/NEJMoa1107039.

[52] Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation // N Engl J Med. 2011. Vol. 365. P. 981–992. DOI: 10.1056/NEJMoa1107039

[53] Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. DOI: 10.1056/NEJMoa1310907

[54] Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation // N Engl J Med. 2013. Vol. 369. P. 2093–2104. DOI: 10.1056/NEJMoa1310907

[55] Karcioglu O, Zengin S, Ozkaya B, et. al. Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal. Cardiovasc Hematol Agents Med Chem. 2022;20(2):103-113. DOI: 10.2174/1871525719666210914110750. PMID: 34521332.

[56] Karcioglu O., Zengin S., Ozkaya B., et al. Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal // Cardiovasc Hematol Agents Med Chem. 2022. Vol. 20, No. 2. P. 103-113. DOI: 10.2174/1871525719666210914110750. PMID: 34521332

[57] Pare G, Eriksson N. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127;1404–1412. DOI: org/10.1161/CIRCULATIONAHA.112.001233

[58] Pare G., Eriksson N. Genetic determinants of dabigatran plasma levels and their relation to bleeding // Circulation. 2013. Vol. 127. P. 1404–1412

[59] Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–399. PMID: 18006647. DOI: 10.1124/dmd.107.019083

[60] Blech S., Ebner T., Ludwig-Schwellinger E., et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans // Drug Metab Dispos. 2008. Vol. 36. P. 386–399. DOI: 10.1124/dmd.107.019083

[61] Laizure SC, Parker RB, Herring VL, et al. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab Dispos. 2014;42(2):201–206. DOI: 10.1124/dmd.113.054353. Epub 2013 Nov 8. PMID: 24212379

[62] Laizure S.C., Parker R.B., Herring V.L., et al. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis // Drug Metab Dispos. 2014. Vol. 42, No. 2. P. 201–206. DOI: 10.1124/dmd.113.054353. Epub 2013 Nov 8. PMID: 24212379

[63] Bernier M, Lancrerot SL, Parassol N, et al. Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio. J Cardiovasc Pharmacol. 2020;76(4):472–477. DOI: 10.1097/FJC.0000000000000870

[64] Bernier M., Lancrerot S.L., Parassol N., et al. Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio // J Cardiovasc Pharmacol. 2020. Vol. 76, No. 4. P. 472–477. DOI: 10.1097/FJC.0000000000000870

[65] Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor. Curr Clin Pharmacol. 2014;9(1):75–83. DOI: 10.2174/1574884708666131111204658

[66] Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor // Curr Clin Pharmacol. 2014. Vol. 9, No. 1. P. 75–83. DOI: 10.2174/1574884708666131111204658

[67] Frost C, Garonzik S, Shenker A, et al. Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration. Clin Pharmacol Drug Dev. 2021;10(9):974–984. DOI: 10.1002/cpdd.990

[68] Frost C., Garonzik S., Shenker A., et al. Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration // Clin Pharmacol Drug Dev. 2021. Vol. 10, No. 9. P. 974–984. DOI: 10.1002/cpdd.990

[69] Hanigan S, Das J, Pogue K, et al. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. 2020;49(4): 636–643. DOI: 10.1007/s11239-020-02037-3. PMID: 31925665

[70] Hanigan S., Das J., Pogue K., et al. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding // J Thromb Thrombolysis. 2020. Vol. 49, No. 4. P. 636–643. DOI: 10.1007/s11239-020-02037-3

[71] Steffel J, Collins R, Antz M. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021:1–65. DOI:10.1093/europace/euab065

[72] Steffel J., Collins R., AntzM. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation // Europace. 2021. P. 1–65. DOI: 10.1093/europace/euab065

[73] Ionin VA, Bliznyuk OI, Baranova EI, et al. Anticoagulant therapy in patients with non-valvular atrial fibrillation in real clinical practice: unreasonable use of reduced doses. Rational Pharmacotherapy in Cardiology. 2021;2(17):206–211. DOI: 10.20996/1819-6446-2021-03-04

[74] Ионин В.А., Близнюк О.И., Баранова Е.И. и др. Антикоагулянтная терапия у больных с неклапанной фибрилляцией предсердий в реальной клинической практике: необоснованное применение сниженных доз // Рациональная Фармакотерапия в Кардиологии. 2021. Т. 2. № 17. P. 206–211. DOI: 10.20996/1819-6446-2021-03-04

[75] Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(15):955–96. D0I: 10.1016/S0140-6736(13)62343-62350

[76] Ruff C.T., Giugliano R.P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials // Lancet. 2014. Vol. 383, No. 15. P. 955–96. DOI: 10.1016/S0140-6736(13)62343-62350

[77] Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–62. DOI: 10.1182/blood-2014-03-563577.124:955-962

[78] Beyer-Westendorf J., Förster K., Pannach S., et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry // Blood. 2014. Vol. 124, No. 6. P. 955-62. DOI: 10.1182/blood-2014-03-563577.124:955-962

[79] Testa S, Ageno W, Antonucci E, et al. Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. InternEmergMed. 2018;13(7):1051–1058. DOI: 10.1007/s11739-018-1877-z

[80] Testa S., Ageno W., Antonucci E., et al. Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry // InternEmergMed. 2018. Vol. 13, No. 7. P.1051-1058. DOI: 10.1007/s11739-018-1877-z

[81] Cangemi DJ, Krill T, Weideman R ed al. A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin. Am J Gastroenterol. 2017;112(5):734–739. DOI: 10.1038/ajg.2017.39.

[82] Cangemi D.J., Krill T., Weideman R., ed al. A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin // Am J Gastroenterol. 2017. Vol. 112, No. 5. P. 734-739. DOI: 10.1038/ajg.2017.39

[83] Kakkar AK, Mueller I, Bassand JP, et al «International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)». AHJ. 2012;163(1):13–19. DOI: 10.1016/j.ahj.2011.09.011

[84] Kakkar A.K., Mueller I., Bassand J.P., et al. «International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD) // AHJ. 2012. Vol. 163, No. 1. P. 13–19. DOI: 10.1016/j.ahj.2011.09.011

[85] Becattini C, Franco L, Beyer-Westendorf J, et al. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. Int J Cardiol. 2017;227:261–266. DOI: 10.1016/j.ijcard.2016.11.117

[86] Becattini C., Franco L., Beyer-Westendorf J., et al. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life // Int J Cardiol. 2017. Vol. 227. P. 261–6. DOI: 10.1016/j.ijcard.2016.11.117

[87] Yuhara H, Corley DA, Nakahara F, et al. Aspirin and non-aspirin NSAIDs increase risk of colonic diverticular bleeding: a systematic review and meta-analysis. J Gastroenterol. 2014;49:992–1000. DOI: 10.1007/s00535-013-0905-z

[88] Yuhara H., Corley D.A., Nakahara F., et al. Aspirin and non-aspirin NSAIDs increase risk of colonic diverticular bleeding: a systematic review and meta-analysis // J Gastroenterol. 2014. Vol. 49. P. 992–1000. DOI: 10.1007/s00535-013-0905-z

[89] Kropacheva ES, Khakimova MB, Krivosheeva EN, et al. Severe gastrointestinal bleeding in patients with atrial fibrillation receiving oral anticoagulants (based on REGistry of long-term AnTithrombotic TherApy – REGATTA). Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93 (9):1037–1043. DOI: 10.26442/00403660.2021.09.201019

[90] Кропачева Е.С., Хакимова М.Б., Кривошеева Е.Н. и др. Тяжелые желудочно-кишечные кровотечения у больных с фибрилляцией предсердий, получающих пероральные антикоагулянты (по данным двадцатилетнего наблюдения в рамках РЕГистра длительной Антитромботической ТерАпии – РЕГАТА) // Терапевтический архив. 2021. Т. 93, № 9. C. 1037–1043. DOI: 10.26442/00403660.2021.09.201019

[91] Mihalkanin L, Stancak B. The Impact of Novel Anticoagulants on the Upper Gastrointestinal Tract Mucosa. Medicina (Kaunas). 2020;56(7):363. DOI: 10.3390/medicina56070363.

[92] Mihalkanin L., Stancak B. The Impact of Novel Anticoagulants on the Upper Gastrointestinal Tract Mucosa // Medicina (Kaunas). 2020. Vol. 56, No. 7. P. 363. DOI: 10.3390/medicina56070363.

[93] Camm AJ, Pinto FJ, Hankey GJ, et al. Writing Committee of the Action for Stroke Prevention alliance. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace. 2015;17(7):1007-1017. DOI: 10.1093/europace/euv068. PMID: 26116685

[94] Camm A.J., Pinto F.J., Hankey G.J., et al. Writing Committee of the Action for Stroke Prevention alliance. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation // Europace. 2015. Vol. 17, No. 7. P. 1007–1017. DOI: 10.1093/europace/euv068

[95] Miller CS, Dorreen A, Martel M; et al. Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017;15(11):1674–1683.e3. DOI:10.1016/j.cgh.2017.04.031

[96] Miller C.S., Dorreen A., Martel M., et al. Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis // Clin Gastroenterol Hepatol. 2017. Vol. 15, No. 11. P. 1674–1683.e3. DOI: 10.1016/j.cgh.2017.04.031

[97] Kirchhof P, Radaideh G, Kim YH, et al. Global XANTUS program Investigators. Global Prospective Safety Analysis of Rivaroxaban. J Am Coll Cardiol. 2018;7(2):141–153. DOI: 10.1016/j.jacc.2018.04.058

[98] Kirchhof P., Radaideh G., Kim Y.H., et al. Global XANTUS program Investigators. Global Prospective Safety Analysis of Rivaroxaban // J Am Coll Cardiol. 2018. Vol. 72, No. 2. Р. 141–153. DOI: 10.1016/j.jacc.2018.04.058

[99] Lauffenburger JC, Farley JF, Gehi AK, et al. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol. 2015;115(8):1095–1101. DOI: 10.1016/j.amjcard.2015.01.539

[100] Lauffenburger J.C., Farley J.F., Gehi A.K., et al. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States // Am J Cardiol. 2015. Vol. 115, No. 8. P.1095–1101. DOI: 10.1016/j.amjcard.2015.01.539

[101] Golitsyn SP, Panchenko EP, Kropacheva ES. Eurasian clinical guidelines for the diagnosis and treatment of atrial fibrillation. 2020. 95 p. (In Russ.)

[102] Голицын С.П., Панченко Е.П., Кропачева Е.С. Евразийские клинические рекомендации по диагностике и лечению фибрилляции предсердий. 2020. 95 c.

[103] O’Brien EC, Holmes DN, Thomas L, et al. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation. 2018;138(9):889–897.

[104] O’Brien E.C., Holmes D.N., Thomas L., et al. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation // Circulation. 2018. Vol. 138, No. 9. P. 889–897.

[105] Kirchhof P, Camm AJ, Goette A ed al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305–1316. DOI: 10.1056/NEJMoa2019422

[106] Kirchhof P., Camm A.J., Goette A., et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation // N Engl J Med. 2020. Vol. 383, No. 14. P. 1305–1316. DOI: 10.1056/NEJMoa2019422

[107] Lavalle C, Di Lullo L, Bellasi A, et al. Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network. Cardiorenal Med. 2020;10(4):266-276. DOI: 10.1159/000507046

[108] Lavalle C., Di Lullo L., Bellasi A., et al. Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network // Cardiorenal Med. 2020. Vol. 10, No. 4. P. 266–276. DOI: 10.1159/000507046

[109] Ingason AB, Hreinsson JP, Agustsson AS, et al. Warfarin is associated with higher rates of upper but not lower gastrointestinal bleeding compared to direct oral anticoagulants: a population-based propensity-weighted cohort study. Clin. Gastroenterology Hepatol. 2023;21(2):347-357. DOI: 10.1016/j.cgh.2022.06.033

[110] Ingason A.B., Hreinsson J.P., Agustsson A.S., et al. Warfarin is associated with higher rates of upper but not lower gastrointestinal bleeding compared to direct oral anticoagulants: a population-based propensity-weighted cohort study // Clin. Gastroenterology Hepatol. 2023. Vol. 21. No. 2. P. 347–357. DOI: 10.1016/j.cgh.2022.06.033

[111] Bansilal S, Bloomgarden Z, Halperin JL, et al. ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015;170(4):675–682.e8. DOI: 10.1016/j.ahj.2015.07.006

[112] Bansilal S., Bloomgarden Z., Halperin J.L., et al. ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial // Am Heart J. 2015. Vol. 170, No. 4. P. 675–682.e8. DOI: 10.1016/j.ahj.2015.07.006

[113] Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2372. DOI: 10.1161/CIRCULATIONAHA.110.004747

[114] Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial // Circulation. 2011. Vol. 123, No. 21. P. 2363–2372. DOI:10.1161/CIRCULATIONAHA.110.004747

[115] Arutyunov GP, Fomin IV, Tarlovskaya EI, et al. Algorithm for assessing and modifying risk factors for minor bleeding in patients with atrial fibrillation receiving POAC therapy. Resolution of the Eurasian Association of Therapists. 2020. 30 p. (In Russ.)

[116] Арутюнов Г.П., Фомин И.В., Тарловская Е.И. и др. Алгоритм оценки и модификации факторов риска небольших кровотечений у пациентов с фибрилляцией предсердий, получающих терапию ПОАК. Резолюция Евразийской ассоциации терапевтов. 2020. 30 с.

[117] Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33(8):1027–35. DOI: 10.1016/j.cjca.2017.06.001

[118] Bosch J., Eikelboom J.W., Connolly S.J., et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial // Can J Cardiol. 2017. Vol. 33, No. 8. P. 1027–1035. DOI: 10.1016/j.cjca.2017.06.001

[119] Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2021. Endoscopy. 2021;53(3):300–332. DOI: 10.1055/a-1369-5274

[120] Gralnek I.M., Stanley A.J., Morris A.J., et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2021 // Endoscopy. 2021. Vol. 53, No. 3. P. 300–332. DOI: 10.1055/a-1369-5274

[121] Ishiyama H, Yamasaki K, Kanbe T. Effect of proamipide (OPC-12759) on gastric mucus secretion in rats. Jpn Pharmacol Ther. 1988;16:4103–109.

[122] Ishiyama H., Yamasaki K., Kanbe T. Effect of proamipide (OPC-12759) on gastric mucus secretion in rats // Jpn Pharmacol Ther. 1988. Vol. 16. P. 4103–109.

[123] Yoshikawa T, Naito Y, Nakamura S, et al. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indometacin in rats. Arzneimittelforschung. 1993;43(12):1327–1330.

[124] Yoshikawa T., Naito Y., Nakamura S., et al. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indometacin in rats // Arzneimittelforschung. 1993. Vol. 43, No. 12. P. 1327–1330.

[125] Suzuki M, Miura S, Mori M, et al. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidant. Gut. 1994;35(10):1375–1378. DOI: 10.1136/gut.35.10.1375

[126] Suzuki M., Miura S., Mori M., et al. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants // Gut. 1994. Vol. 35, No. 10. P. 1375–1378. DOI: 10.1136/gut.35.10.1375

[127] Aihara M, Azuma A, Takizawa H, et al. Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. 1998;43(9 Suppl): 174S–180S.

[128] Aihara M., Azuma A., Takizawa H., et al. Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. 1998. Vol. 43, No. 9. P. 174S–180S.

RIGHTS & PERMISSIONS

Eco-Vector